June 19th, 2018 – Adastra Labs Holdings Ltd. (“Adastra” or the “Company”) announces the hiring of Andrew Hale, MBA, BSAE, PMP as CEO of Adastra Labs Holdings Ltd. and Adastra Labs Inc. “As a co-founder and now the CEO, Andy brings decades of leadership and management experience to Adastra. As a served US Navy nuclear powered submarine commander and more recently Vice President at Vancouver Shipyards, he brings leadership, drive and technical acumen to the Adastra team,” stated co-founder Justin Manuel.
Mr. Hale is a seasoned leader of high performing teams delivering operations and complex program excellence. He attended the United States Naval Academy at Annapolis where he earned a Bachelor of Science in Aerospace Engineering. Mr. Hale served in the U.S. Navy as a career nuclear-powered submarine officer. He had the rare privilege to command three nuclear-powered submarines in the U.S. Navy where he led all aspects of operations, training, logistics and personnel, with ultimate responsibility for mission accomplishment on $4B national assets. Mr. Hale earned his Masters in Business Administration from the University of Massachusetts at Amherst at the tail end of his naval career. Following his successful naval career, he was selected to transition to the U.S. federal civil service as a Senior Executive in the Department of Energy at Headquarters Naval Reactors to run all aspects of the entire Naval Nuclear Propulsion Training Program. His stewardship extended to three sites including four operating prototype nuclear reactor plants and more than 4,500 personnel. Mr. Hale moved to Vancouver Canada to permanently relocate with his family and entered the revitalized Canadian shipbuilding industry at Seaspan Vancouver Shipyards. He served as Program Director of a complex new construction design and building program and later as Vice President, Program Delivery to oversee all three of Seaspan’s Canadian National Shipbuilding Strategy Non-combat design and build programs valued at over $3B CAD.
For further information, please contact:
Andy Hale, CEO
About Adastra Holdings Ltd.
In Canada, Adastra (through its wholly owned subsidiary, Adastra Labs Inc.) is in the application process to become a Standard Processor under the Cannabis Act administered by Health Canada, with a licence to produce cannabis extracts. This licence will further enable Adastra and its subsidiaries to produce, package, sell (wholesale), and export medically focused and recreational cannabis extract and concentrate products in Canada to other licensed entities and internationally in jurisdictions where medical cannabis extraction products are legal.
The Company’s operations include a facility in British Columbia, Canada. The Company is developing its 13,035 square feet facility to be fully devoted to standard processing by late 2019, from which it expects to produce significant amounts of cannabis oil and/or hemp oil for the Canadian wholesale medical and recreational markets.
The Company will offer a suite of unique products under several existing consumer-focused brands, including tinctures, medicinal oils, concentrates, and when legalized, gel capsules and vaporizer pens. Through acquisition of existing cannabis extraction brands and careful development of its new brands, Adastra will be positioned to be a leader in branded, commercialized products in both the medical and adult-use markets across North America and internationally.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: Adastra’s expectations concerning an increase in its production capacity. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, Adastra assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. SOURCE: Adastra Labs Holdings Ltd.